Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that three abstracts will be presented from the KER-012 program at the Pulmonary Vascular Research Institute (“PVRI”) 2024 Annual Congress, to be held from January 31 through February 3, 2024.

Clinical Presentations

“Development of KER-012, a Novel Investigational Activin Receptor Type IIB Ligand Trap with High Activin/GDF Specificity and Target Engagement for the Treatment of Pulmonary Arterial Hypertension: Rationale and Design of the TROPOS Phase 2 Study”

• Presenter: Marc Humbert, M.D., Ph.D., Professor of Respiratory Medicine at the Université Paris-Saclay
• Date: February 2, 2024
• Presentation Time: 4:30 - 6:00 p.m. GMT
  

“Administration of KER-012 to Healthy Post-Menopausal Women Elicited Biomarker Changes Suggesting Anti-Inflammatory and Anti-Fibrotic Effects That Target the Pathophysiology of Pulmonary Arterial Hypertension”

• Presenter: M. Kathryn Steiner, M.D., Keros
• Date: February 2, 2024
• Presentation Time: 4:30 - 6:00 p.m. GMT
  

Preclinical Presentation

“RKER-012, A Novel Modified ActRIIB Ligand Trap, Reduced Pulmonary Vascular Pathology in a Rat Model of Pulmonary Arterial Hypertension”

• Presenter: Keith Babbs, Ph.D., Keros
• Date: February 2, 2024
• Presentation Time: 4:20 p.m. GMT
  

About TROPOS

TROPOS is a randomized, double-blind, placebo-controlled, global Phase 2 clinical trial to evaluate KER-012 in combination with background therapy in patients with pulmonary arterial hypertension (“PAH”). The primary objective of this trial is to evaluate the effect of KER-012 on pulmonary hemodynamics compared to placebo in participants on background PAH therapy. The key secondary objective of this trial is to evaluate the effect of KER-012 on exercise capacity compared to placebo on participants on background PAH therapy.